Josh Cohen (L) and Justin Klee (Amylyx)
A pair of young biotech execs snag a mega-round for their late-stage ALS drug as the FDA signals a more flexible approach to an OK
Five years after Justin Klee and Josh Cohen got a little seed cash from the late Boston biotech legend Henri Termeer to see if they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
